Literature DB >> 20209638

Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status.

Aileen E Marshall1, Simon M Rushbrook, Sarah L Vowler, Christopher R Palmer, R Justin Davies, Paul Gibbs, Susan E Davies, Nicholas Coleman, Graeme J M Alexander.   

Abstract

The selection of patients with hepatocellular carcinoma for liver transplantation is currently based on the size and number of tumors to minimize the risk of recurrence. These criteria measure tumor bulk but may not reflect tumor behavior accurately. A biological marker of tumor behavior could aid with patient selection further. The aims of this study were to determine factors associated with a higher risk of tumor recurrence and to assess the role of tumor proliferation status with respect to recurrence following transplantation. Pathological data on 67 patients who underwent transplantation for hepatocellular carcinoma were reviewed, and tumor proliferation was assessed by minichromosome maintenance protein-2 (MCM-2) and cyclin A expression. A Cox regression analysis of factors related to tumor recurrence and overall survival was carried out. Recurrence-free survival was assessed according to compatibility with selection criteria, vascular invasion, and proliferation status. Tumor size, vascular invasion, and highest MCM-2 expression were associated with tumor recurrence by multivariate analysis (P < 0.02). Recurrence-free survival was significantly better for those patients without vascular invasion, those who were within the Milan, University of California San Francisco (UCSF), or Up-to-Seven selection criteria, and those with lower expression of MCM-2. In conclusion, tumors meeting the Milan, UCSF, or Up-to-Seven selection criteria had a lower rate of recurrence following liver transplantation. Vascular invasion and tumor proliferation status were associated with the risk of recurrence independently of tumor size. Biopsy of larger tumors to assess proliferative activity could identify those at lower risk of recurrence who could also benefit from liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209638     DOI: 10.1002/lt.21993

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Liver transplantation for advanced hepatocellular carcinoma: how far can we go?

Authors:  Kyung-Suk Suh; Hae Won Lee
Journal:  Hepat Oncol       Date:  2015-01-12

2.  Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Somsak Likhitrattanapisal; Jaitip Tipanee; Tavan Janvilisri
Journal:  Tumour Biol       Date:  2016-07-22

3.  Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion.

Authors:  See Ching Chan; Sheung Tat Fan; Kenneth S H Chok; Tan To Cheung; Albert C Y Chan; James Y Y Fung; Ronnie T P Poon; Chung Mau Lo
Journal:  Hepatol Int       Date:  2011-10-21       Impact factor: 6.047

4.  Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series.

Authors:  Cem Simsek; Amy Kim; Michelle Ma; Nilay Danis; Merve Gurakar; Andrew M Cameron; Benjamin Philosophe; Jacqueline Garonzik-Wang; Shane Ottmann; Ahmet Gurakar; Behnam Saberi
Journal:  Hepatoma Res       Date:  2020-03-20

5.  Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma.

Authors:  Tingfeng Xu; Liying Ren; Minjun Liao; Bigeng Zhao; Rongyu Wei; Zhipeng Zhou; Yong He; Hao Zhang; Dongbo Chen; Hongsong Chen; Weijia Liao
Journal:  J Hepatocell Carcinoma       Date:  2022-03-20

6.  Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT).

Authors:  Matteo Renzulli; Margherita Mottola; Francesca Coppola; Maria Adriana Cocozza; Silvia Malavasi; Arrigo Cattabriga; Giulio Vara; Matteo Ravaioli; Matteo Cescon; Francesco Vasuri; Rita Golfieri; Alessandro Bevilacqua
Journal:  Cancers (Basel)       Date:  2022-04-03       Impact factor: 6.639

7.  Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Liang Sang; Xue-Mei Wang; Dong-Yang Xu; Wen-Jing Zhao
Journal:  World J Gastroenterol       Date:  2018-06-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.